University of Durham

Pleco Therapeutics is proud to announce the publication of a research paper, "Synthesis of Metal-Binding Amino Acids," in Organic & Biomolecular Chemistry. Authored by PhD-student Katherine Deck and Associate Professor Will Brittain from Durham University, UK. The paper outlines recently developed strategies for the synthesis of metal binding non-proteinogenic amino acids, which an essential part of ongoing efforts to explore novel therapies. Pleco’s support is mentioned under Acknowledgements, for which we thank the authors. This work is part of our ongoing collaborations with academic centres around the world, including Durham University, where our focus is on investigating basic mechanisms of chemoresistance. These developments align with Pleco Therapeutics' mission to enhance chemotherapy efficacy and overcome treatment resistance in cancer. We extend our congratulations to Katherine Deck and Will Brittain for their contribution. Click here for article

本月，英国纽卡斯尔大学携手杜伦大学、华威大学、圣安德鲁斯大学和埃克塞特大学，一同在北京和上海举办了「2024中国线下招聘会」，帮助超过1000名毕业生顺利完成求职面试🎉！ 在这场为期三天的大型招聘会中，多家海内外知名企业雇主亲临现场，其中包括：特斯拉、汇丰、阿里云、伦敦证券交易所LSEG、京东、联想、戴尔、宁德时代、荣耀、雀巢、蒙牛、米哈游、英国文化教育协会（British Council）等。各大企业也提供了丰富的岗位选择，包括但不限于：算法、计算机、工程师、新能源、企业管培生、市场、媒体、教育等。 多年来，英国纽卡斯尔大学始终致力于为已毕业的校友和在校学生们提供求职就业指导。除了此类大型线下招聘活动，学校也针对大家关心的「寻找实习与志愿机会」、「求职材料准备」和「创业支持」提供完备服务。 “2025年QS世界大学排名中，英国纽卡斯尔大学「就业能力」荣获五星评级。” 即刻下滑阅读，了解并用好英国纽卡斯尔大学的各类就业资源，制胜“金九银十”招聘季！ 🙋在读学生 🎓近三年毕业校友 💬 一对一咨询 ✏️ 个性化辅导 💡 就业研讨会 🤝 线下招聘会      实习机会与志愿活动 🙌 在读本科生和研究生可申请 ✔️ 学期期间和暑期期间均提供实习机会 ⌚️ 暑期实习可以选择全职，也可根据个人情况灵活安排时间 💰 校园实习按小时提供酬劳，当地企业实习提供免税奖学金 💼 深入了解特定工作角色或领域，提前探索未来职业兴趣 长按扫描下方二维码 查找并申请实习机会      简历撰写与面试指导 📒 简历与求职信撰写指导 📃 在线求职申请表填写辅导 🔍 LinkedIn领英个人资料填写指南 📝 涵盖逻辑、性格、心理、游戏式评估、各类专科测试的海量题库 🧑🏫 一对一面试辅导 📬 Offer接受及薪资洽谈指导      创业扶持 💰 通过评选的创业项目可获得高达£3,000的创业启动资金 🙋 与拥有自主创业一手经验的求职顾问进行一对一会谈 👥 参加研讨会，认识志同道合的合作伙伴 💻 在纽卡斯尔Helix、Floe、TusPark、Northern Design Centre、PROTO等蓬勃发展的创业环境中自由成长 长按扫描下方二维码 了解创业扶持      报名进行中｜留学生就业指导项目 自2018年起，英国纽卡斯尔大学Career Service已连续六年举办「China Career Gateway中国留学生就业服务指导专项项目」，为超过1000名同学提供就业指导。 🔍 你将在项目中获得什么？ 全面了解中英两国职场 掌握高效申请中英两国工作岗位的秘诀 克服就业难题，在激烈的竞争中脱颖而出 2024年China Career Gateway活动将于10月7日重磅来袭，报名通道现已开启，欢迎同学们长按扫描下方二维码注册参加，为顺利斩获心仪Offer做好准备！ —— 更多精彩 —— —— 关注我们 —— —— 联系我们 —— 📪 邮箱｜China.IO@ncl.ac.uk ☎️ 电话｜ +44 191 208 6000 💻 官网｜www.ncl.ac.uk

Biogen and Eisai’s Alzheimer’s disease (AD) drug has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat patients with early stages of the neurodegenerative disease, but has not been recommended by the National Institute of Health and Care Excellence (NICE) for use on the NHS in England and Wales. Leqembi (lecanemab) has been authorised by the MHRA to treat mild cognitive impairment and mild dementia due to AD in adults who have one or no copies of the apolipoprotein E4 gene. However, in a blow to patients, NICE has stated in draft guidance that the drug’s benefits are “too small to justify the costs”. An estimated 982,000 people in the UK are living with dementia and AD accounts for the majority of cases. Administered intravenously in a healthcare setting every two weeks, Leqembi works by binding to and reducing clumps of amyloid beta protein that form plaques in the brain. The MHRA’s decision makes Leqembi the first medicine to be licensed in the UK that has been shown to slow progression of the disease and was supported by results from the late-stage Clarity AD trial, in which Leqembi reduced clinical decline by 27% compared with placebo at 18 months. Eisai, which serves as the lead for the drug’s development and regulatory submissions globally, also recently presented positive three-year data from an open-label extension of the study. Despite the improvements observed, an independent NICE committee said: “The costs of providing the treatment, including fortnightly infusions in hospital and intensive monitoring for side effects, combined with the relatively small benefits it provides to patients means it cannot be considered good value for the taxpayer.” Alzheimer’s Research UK’s chief executive, Hilary Evans-Newton, described the news as “bittersweet”. “It’s a remarkable achievement that science is now delivering licensed treatments that can slow down the devastating effects of Alzheimer’s, rather than just alleviating its symptoms. However, it’s clear our health system isn’t ready to embrace this new wave of Alzheimer’s drugs,” she said. Professor Andy Whiting, emeritus professor at Durham University and chief executive officer and co-founder of Nevrargenics, a Durham spinout company developing drugs for neurodegenerative diseases including Alzheimer’s, said in response to today’s news: “While the MHRA approval of [Leqembi] is obviously a step forward for the pharma industry, the NICE rejection reinforces the need for the biotech and pharma community to focus on better balancing of cost versus effectiveness in drug development. “[Leqembi] only targets the symptoms – the plaques – rather than the cause of those plaques. For a new drug to provide value, the impact needs to be higher, which requires our industry to develop bolder drugs for neurodegeneration that target the cause of the disease, not just the symptoms.” NICE’s independent committee will consider responses from a public consultation at a second meeting later this year before producing its final recommendations.